Patients receiving bebtelovimab have more comorbidities, but do not have increased rates of progression to severe disease
Twelfth Version of Living Guideline Issued for Drugs for COVID-19
New update strongly recommends against use of sotrovimab and casirivimab-imdevimab for patients with COVID-19
SARS-CoV-2 mAbs Continued to Be Used After FDA Deauthorization
More than 158,000 doses of bamlanivimab-etesevimab and casirivimab-imdevimab were used after deauthorization on Jan. 24, 2022
Rates of Severe COVID-19 Lower With Nirmatrelvir in ≥65s
Rate of hospitalization due to COVID-19 and death reduced for treated versus untreated patients among those aged 65 years and older
Metformin, Ivermectin, Fluvoxamine Do Not Prevent Severe COVID-19
No difference in the primary end point seen with any of the three medications versus placebo among adults with overweight or obesity
Dupilumab Studied in Patients Hospitalized for COVID-19
No difference seen between dupilumab and placebo groups in adverse events or primary outcome of ventilator-free survival at 28 days
Survival Benefit With Triple Therapy for Severe COVID-19
Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay
Survival Benefit Seen With Triple Therapy for Severe COVID-19
Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay
WHO Guideline Advises Against Fluvoxamine, Colchicine for COVID-19
For nonsevere COVID-19, 11th version of living guideline recommends against fluvoxamine (except in context of clinical trial), colchicine
Asthma Drug Fluticasone Fails as Potential COVID-19 Treatment
Finding from a nationwide study of 5,000 participants that continues to evaluate existing drugs to treat mild-to-moderate COVID-19